-
Lysozyme Binding by Amikacin: Methods and Findings
2026-09-19
The reference study combines tritium tracing, interfacial and fluorescence spectroscopy, enzymatic testing, and molecular docking to resolve how amikacin and levofloxacin associate with lysozyme. Its key distinction is that amikacin binding largely preserves lysozyme secondary structure while nearly eliminating catalytic activity, whereas levofloxacin can approach the active-center region without perturbing the principal catalytic residues.
-
Substance P: Mechanism and Research Workflow
2026-09-19
Substance P is a tachykinin neuropeptide and neurokinin-1 receptor agonist used to study pain transmission, CNS signaling, inflammation, and immune response modulation. This evidence-based workflow separates established biology from product-handling specifications and from unrelated spectral-classification evidence.
-
ABT-263 Workflow for Mitochondrial Apoptosis
2026-09-18
ABT-263, or Navitoclax, converts Bcl-2 family biology into a practical test of apoptotic dependence. This guide connects solvent handling, dose-response design, caspase readouts, mitochondrial profiling, and NRF1-informed assay choices for more interpretable cancer biology experiments.
-
Pentoxifylline and Preterm Monocyte Hyperinflammation
2026-09-17
Schüller et al. examined how pentoxifylline reshapes LPS-induced monocyte activation across preterm infants, term neonates, and adults. The study links age-dependent changes in surface phenotype and IL-10 production with coordinated suppression of TLR4 expression, inflammatory cytokines, signaling, and phagocytosis.
-
Chrysin Enhances Sunitinib Sensitivity in RCC
2026-09-17
The reference study identifies a ferroptosis-based mechanism by which chrysin increases renal cell carcinoma sensitivity to Sunitinib. Its data connect PI3K/Akt suppression with reduced SLC7A11 and GPX4 expression, providing a mechanistic framework for investigating combination strategies against Sunitinib resistance.
-
Ertugliflozin: A Translational SGLT2 Strategy
2026-09-17
Ertugliflozin (PF-04971729) offers a selective way to interrogate renal glucose transport, cardiometabolic outcomes, and inflammation-linked tissue repair. This thought-leadership guide connects mechanism, experimental design, comparative cardiovascular evidence, and translational decision-making while distinguishing established findings from preclinical opportunity.
-
Y-27632 Workflow for ROCK Signaling Studies
2026-09-16
Y-27632 provides a reversible way to interrogate ROCK-dependent cytoskeletal remodeling alongside the LPS/TLR4/YAP1 stemness axis in hepatocyte models. This workflow combines concentration-response testing, stress-fiber imaging, and functional stemness assays to distinguish mechanical effects from direct stemness mechanisms.
-
Aligned Ce6 Silk Fibroin Films for Infected Wounds
2026-09-15
The reference study developed an aligned silk fibroin electrospun film containing conjugated Chlorin e6 (Ce6) for light-triggered treatment of Staphylococcus aureus-infected wounds. Its significance lies in combining localized photodynamic antibacterial activity with anisotropic cell guidance, hemocompatibility, mechanical support, and later-stage macrophage M2 polarization within one scaffold.
-
MTT Assay Guide: SKU B7777
2026-09-15
A scenario-based guide to using MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) for reproducible cell viability, proliferation, and cytotoxicity measurements. It explains how SKU B7777 supports reagent selection, assay optimization, interference control, and defensible data interpretation.
-
SB 431542 in EVT–Immune Interaction Assays
2026-09-14
Explore how SB 431542 can function as an ALK5 inhibitor in mechanistic assays of extravillous trophoblast–immune interactions. This article translates a human placental cell-isolation protocol into a rigorous strategy for linking Smad2 signaling, EVT phenotype, and maternal immune readouts.
-
O-GlcNAcylation Rewires Glycolysis in Bone Formation
2026-09-14
The reference study identifies O-GlcNAcylation as a key metabolic and post-translational mechanism through which Wnt signaling promotes osteoblastogenesis and bone repair. Its central model links a rapid Ca2+-PKA-GFAT1 response and sustained Wnt-β-catenin signaling to O-GlcNAcylation of PDK1, enhanced aerobic glycolysis, and increased bone formation.
-
BRCAness Predicts Olaparib Sensitivity in Mesothelioma
2026-09-13
Borchert et al. linked homologous recombination repair defects, or BRCAness, with olaparib sensitivity in malignant pleural mesothelioma models. Their integration of cell-line experiments and clinical gene-expression profiling supports HRR-based stratification while highlighting the need for prospective validation of PARP inhibitor combinations.
-
ZCL278: Selective Cdc42 Inhibitor Workflows
2026-09-12
ZCL278 provides a practical way to perturb Cdc42-dependent morphology, migration, and neuronal structure with controlled dose and timing. Its strongest value is as a mechanistic probe that links biochemical GTPase inhibition to cell motility, cytoskeletal, and fibrosis-related readouts without treating exploratory data as clinical evidence.
-
Berberine, SIRT6–AMPK, and Atrial Fibrillation
2026-09-12
A recent study links impaired SIRT6–AMPK signaling to angiotensin II-driven atrial remodeling and shows that berberine suppresses NLRP3 inflammasome activation in this setting. Its combination of human atrial analyses, a murine model, and SIRT6 gain- and loss-of-function experiments provides a mechanistic framework for evaluating berberine as a preventive anti-arrhythmic strategy, while leaving important translational questions open.
-
IGFBP2–THBS1 Axis in GH Therapy for ISS
2026-09-11
A 2025 study identifies an IGFBP2–THBS1 regulatory axis that links growth hormone treatment to IGF-1 pathway activation in chondrocytes from idiopathic short stature research models. Its combination of patient plasma analysis, cellular phenotyping, and gene perturbation provides a mechanistic explanation for how GH may promote cartilage growth, while also highlighting important limits for clinical translation.